抗病毒治疗对机械通气患者BAL液中HSV-1阳性的结局影响:回顾性队列研究
该回顾性队列研究纳入4个ICU中机械通气且BAL液HSV-1 PCR阳性的成人呼吸道感染患者306例,比较接受与未接受抗病毒治疗者的30天生存。抗病毒组30天全因死亡率42.4%,对照组50.4%,校正HR 0.62(95%CI 0.44-0.87;非免疫抑制亚组也见获益(校正HR 0.53;95%CI 0.36-0.78;
要点
- 机械通气患者BAL液HSV-1阳性时,抗病毒治疗与30天生存改善独立相关。
- 非免疫抑制患者亚组同样观察到抗病毒治疗与30天生存改善相关。
- 抗病毒组住院、ICU停留及机械通气时间更长,需RCT证实后再常规应用。
核心结论
- BAL液检出HSV-1可能具有临床意义,特异性抗病毒治疗可能改善临床结局,但需多中心RCT证实后方可常规实施。
研究设计与样本
- 纳入机械通气、呼吸道感染且BAL液HSV-1 PCR阳性的成人患者,排除BAL当日已接受抗病毒药物者。
- 共纳入306例患者,采用单因素和多因素Cox及logistic回归建模。
主要发现
- 抗病毒组177例(57.8%)接受治疗,其中90.9%为阿昔洛韦、6.2%为更昔洛韦、2.9%两者兼用。
- 抗病毒组30天总体死亡率为42.4%(n=75),对照组为50.4%(n=65)。
临床怎么用
- 对机械通气且BAL液HSV-1 PCR阳性的呼吸道感染患者,可考虑评估特异性抗病毒治疗,但需结合免疫状态与临床情境个体化决策。
- 因抗病毒组住院、ICU停留及机械通气时间更长,且证据来自回顾性队列,不宜据此常规处方,应等待RCT结果。
局限性
- 回顾性队列设计,可能存在未测量混杂。
- 抗病毒组住院、ICU停留及机械通气时间更长,提示治疗组病情可能更重。
- 作者指出需多中心RCT证实后方可常规临床应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Herpes simplex virus type 1 (HSV-1) is frequently detected in the BAL fluid of patients on mechanical ventilation. RESEARCH QUESTION: The aim of the study was to investigate whether antiviral therapy is associated with improved overall survival within 30 days. STUDY DESIGN AND METHODS: This was a retrospective cohort study in four ICUs between January 2011 and December 2017. All adult patients on mechanical ventilation with a respiratory tract infection with positive polymerase chain reaction testing for HSV-1 in the BAL were included. Patients already receiving antiviral agents on the day BAL was performed were excluded. We performed uni- and multivariable Cox and logistic regression modeling. RESULTS: Overall, 306 patients were included in the analysis. Among them, 177 patients (57.8%) received antiviral therapy (90.9% acyclovir, 6.2% ganciclovir, 2.9% both). The overall 30-day mortality rate was 42.4% (n = 75) in the antiviral treatment group and 50.4% (n = 65) in the control group. The adjusted hazard ratio (HR) for the primary outcome was 0.62 (95% CI, 0.44-0.87; P = .005), indicating better overall survival within 30 days for the antiviral-treated group than for the untreated group. This benefit was also present in the subgroup of patients without immunosuppression (n = 246; adjusted HR, 0.53; 95% CI, 0.36-0.78; P = .001). Overall, the median lengths of hospital stay (31 vs 24 days, P = .002) and ICU stay (24 vs 17 days, P < .001), and the duration of mechanical ventilation (18 vs 11 days, P < .001), were longer for patients with therapy. No evidence for the treatment-related deterioration of renal function was observed. INTERPRETATION: These data suggest that detection of HSV-1 in the BAL of patients on mechanical ventilation may be of clinical significance and that specific antiviral treatment may improve clinical outcomes. However, this needs to be proven in multicenter randomized controlled trials before implementation into the clinical routine.
引用
- Heimes E, Baier M, Forstner C, et al. Effect of Antiviral Therapy on the Outcome of Mechanically Ventilated Patients With Herpes Simplex Virus Type 1 in BAL Fluid: A Retrospective Cohort Study. Chest. 2020. PMID: 32629035. doi:10.1016/j.chest.2020.06.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。